Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 14/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | FOS | P01100 | 2/20 | 0.42 |
| ▸ | JUN | P05412 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14955777 | 0.92 | PTGER1 (0.48) | PTGER1FOSJUNMAPK1MAPK10 | |
| SCHEMBL14956068 | 0.90 | PTGER1 (0.44) | PTGER1CYP1A2THRATHRB | |
| SCHEMBL14955759 | 0.88 | PTGER1 (0.52) | PTGER1CYP1A2THRATHRB | |
| SCHEMBL254655 | 0.88 | PTGER1 (0.52) | PTGER1CYP1A2THRATHRB | |
| SCHEMBL14956205 | 0.88 | PTGER1 (0.43) | PTGER1CYP1A2THRATHRB | |
| SCHEMBL252089 | 0.88 | PTGER1 (0.56) | PTGER1 | |
| SCHEMBL14956121 | 0.87 | PTGER1 (0.47) | PTGER1CYP1A2THRATHRB | |
| SCHEMBL14956274 | 0.86 | PTGER1 (0.48) | PTGER1 | |
| SCHEMBL14955939 | 0.86 | PTGER1 (0.41) | PTGER1CYP1A2 | |
| SCHEMBL14956709 | 0.85 | PTGER1 (0.41) | PTGER1FOSJUNCYP1A2THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2945932-B1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2018-11-21 | — | — | EP | claimed |
| US-9394284-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-07-19 | — | — | US | claimed |
| EP-2945932-B1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-9394284-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394284-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394284-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2945932-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150080446-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080446-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080446-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. | 2015-03-19 | — | — | US | disclosed |
| US-8859606-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859606-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859606-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2014113814-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014113814-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
| US-20130131135-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131135-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131135-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080446-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, CNR1 | PTGER1 1/4885LTB4R 17/4885FOS 1701/4885 |
| US-20130131135-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, CNR1 | PTGER1 1/4885LTB4R 17/4885FOS 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.